Imaware

Imaware

Imaware operates from Austin, providing a health-testing infrastructure that enterprises deploy under their own brands. The platform integrates at-home kit fulfillment, lab processing through Quest and LabCorp facilities, wearable-device data synchronization, and a clinician-facing analytics dashboard. The firm positions the stack as a retention and lifetime-value tool, offering branded health insights that keep end users inside a partner’s ecosystem. Its coverage spans more than 200 analytes across panels configurable for specific populations — corporate wellness cohorts, clinical-trial participants, chronic-condition management groups, and direct-to-consumer health members. The underlying lab network holds CLIA certification and CAP accreditation; the company states 100 percent testing availability across all 50 U.S. states and cites HIPAA compliance. Confirmed customers include the health-content platform run by CEO Ari Tulla, which reported that over 95 percent of beta members improved biomarkers after a six-month program. Staffing, facility, and financial-disclosure figures are not publicly available. The firm’s website signals a B2B-only go-to-market: employers, payors, clinical-care organizations, and pharmaceutical sponsors are the named buyer personas. No fundraising rounds, institutional backers, or adjacent philanthropic vehicles are currently verifiable from public primary sources. Imaware’s structural distinction is its refusal to own the consumer relationship — it supplies the diagnostic rails while the partner owns the brand, the data narrative, and the ongoing engagement. That architecture separates it from direct-to-consumer lab-testing marketplaces and places it closer to an API-first health-data utility for curated populations.